There are several dangers next week. Pitfalls, traps but which way-? Going way back to my original thesis on everything-- The Master Plan... The thought was Inflation comes down rapidly and the market celebrates! Even though earn estimates are coming down... the market celebrates that inflation. So focused. My argument, the market will not be able to control itself. With that understood we have to be aware of how the market will react to a slight bump UP in inflation!/ In my mind right around the 4% mark (2X the target) we were going to have a ratchet up and that was going to freak everyone out. Now that Jobs report... I don't know where that strength came from but it coincides with a pick up in the home builders. For that reason we have to be open to the possibility that a bump up or a ceasing of the decline may happen right now at 6% which would be super scary. I am playing it both ways.. being careful but also 100% invested. Always in my mind is that 4,400 number where the Fed stops being Ok with the market's advance... My bet now is that we do race up to that 4,400, that this reporting cycle we do get further declines in the inflation number // a break above 4,200 will get us there.. the computer action alone. The next time this all rolls around that April-June period I don't feel good about.-~si
Monday - February 13 Volatility watch - Virgin Galactic (SPCE) is positioned again for a volatile week with short interest at a very high level.
BATTLE OF THE MOTHERSHIPS? VZ SPOTTED SOME UNUSUAL ACTIVITY IN SPCE (I THINK OPTIONS) AND I SEE THE NAME HIGHLIGHTED AS HEAVILY SHORTED.... I can't find anything relevant except I do know Musk is about to roll out his mother ship and sometimes Sir Richard gets jealous.. Remember he jumped ahead once before ona test flight. Jan 12> Virgin Galactic says commercial service remains on track to start in Q2 01/12 SPCE The company states: "Virgin Galactic announced its updated leadership structure to support commercial spaceline operations, which are on track for Q2 2023 as previously announced by the Company. The organizational changes will support the Company's core near-term objectives of delivering increased flight frequency and executing on rapid fleet development plans. As part of this leadership update, Swami Iyer, President, Aerospace Systems, will be departing from his position, effective January 12, 2023. He will continue to serve as an advisor to Michael Colglazier, CEO of the Company, until March 3, 2023 to ensure a smooth transition. Planned upgrades of VMS Eve are complete, and the mothership is expected to enter ground tests next week before commencing flight tests to verify the enhancements to the ship. Commercial service remains on track to begin in Q2 2023." A surprise visit perhaps from the SPCE Mothership?
What's up, guys! Hey, we're here, albeit not always peaking. We're always working to make our traders happy so, please ping me directly if you want to discuss anything. You have my attention .
Toast more than just restaurant payments, stock looks like a buy, Barron's says 09:13 FISV, SQ, TOST U.S. diners are finally getting a taste of their international peers' more seamless experience, thanks to next-generation providers like Fiserv's (FISV) Clover, Block's (SQ) Square, and, in particular, Toast (TOST). Sleek terminals for taking orders and payments are the most visible features to diners, but Toast also has a suite of software that aims to act as an operating system for restaurants, Nicholas Jasinski writes in this week's edition of Barron's. It replaces analog or more labor-intensive processes throughout the kitchen and dining room, saving time and effort for staff and customers alike. Toast is powering the digital transformation of a staid industry with low profit margins and demanding customers, the author adds. Toast is a win-win for restaurants and their customers. While it hasn't been for its public investors so far, its future looks more appetizing, Jasinski says
Sometimes you can find good biotech ideas buy watching who others are watching>>> Larger drug co's tend to know which Bios to lock onto and purchase. Barclays views GSK acquisition interest as positive for oncology stocks 01/02 ARVN, GSK, REPL, KURA, IOVA, SNDX, SWTX, BCYC, KPTI Barclays analyst Peter Lawson views the Financial Times' report that GSK (GSK) has interest in acquiring companies with a market capitalization in the $1.0B-$2.5B range, are under-the-radar, and with drugs that can be approved in the medium term as positive for the biotech tape. Renewed acquisition activity would help improve biotech sentiment and the overall index performance, Lawson tells investors in a research note. He sees a positive read-through to oncology companies with late-stage assets, namely Arvinas (ARVN), Replimune Group (REPL), Kura Oncology (KURA), Iovance Biotherapeutics (IOVA), Syndax (SNDX), SpringsWorks Therapeutics (SWTX), Bicycle Therapeutics (BCYC) and Karyopharm (KPTI). I have past experience with BCYC, KPTI, IOVA & have herd good things about Kura.... Each of these names is worthy of further research.-
GET TO KNOW BT8009 preclinical data from BT8009 program was published in the Journal of Medicinal Chemistry. The article, titled "Discovery of BT8009: a Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer" is available at the publications section of the Bicycle website at this link. "The pre-clinical data published in the Journal of Medicinal Chemistry describe the discovery of our clinical-stage Bicycle Toxin Conjugate candidate targeting Nectin-4 expressing tumors," said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. "Together with our study published recently in Molecular Cancer Therapeutics, these articles describe the preclinical work supporting the development of BT8009, which we are currently evaluating in a Phase I/II clinical trial across a number of solid tumor cancers. Nectin-4 is a validated tumor antigen target and we are excited to develop a novel approach to Nectin-4 expressing tumors."